$ACET

$3.90 -$0.04 (1.02%) After hours

$ACET Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 9.4M shares outstanding

Who owns ACET?

By type of holder

Institutions 65.1% Insiders 11.8% Everyone else 23.1%

Concentration Top 10 holders own 51.4%

Ra Capital Management, L.P. 10.0% · Orbimed Advisors LLC 9.0%

Institutional ownership

65.1%

-3.4 pts vs last qtr

Institutional holders

+6 vs last qtr

Net shares bought

−321.2K

by institutions in Q2 2026

New / sold out

12 / 6

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Schonfeld Strategic Advisors LLC NEW +195.5K
Bridgeway Capital Management, LLC NEW +86.0K

Biggest sellers in Q2 2026

Woodline Partners LP SOLD OUT −313.1K
Prosight Management, LP SOLD OUT −250.2K

Who is planning to sell?

Notices of proposed sale, last 12 months

$1.19M

3 notices from 3 people

Shares covered

183.2K

1.96% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

OrbiMed Genesis Master Fund, L.P. Shareholder $514K
OrbiMed Israel Partners Limited Partnership Shareholder $413K

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+25.5%

+25.49% a year

Each share's claim on the business

−20.3%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $36.5M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years24% 3–5 years19% 1–3 years21% Under 1 year36%

Quarterly turnover

14.7%

of institutional shares changed hands

Top 10 managers, median time held

2.3 years

Super Investors

Investment managers reporting ACET on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RC Ra Capital Management, L.P.	932.6K	9.96%	−250.0K (−21.1%)	2024	0.1%
Shares held by quarter Peak holding7.5M (Q3'24) Change over 8 quarters−6.6M Share of the company9.960% Ra Capital Management, L.P.'s full portfolio →
OA Orbimed Advisors LLC 13D · 8.8%	844.8K	9.02%	−183.2K (−17.8%)	≤2021	0.1%
Shares held by quarter Peak holding11.4M (Q3'24) Change over 8 quarters−10.6M Share of the company9.020% Disclosed stake13D · 8.8% Orbimed Advisors LLC's full portfolio →

Ra Capital Management, L.P.

932.6K

% of company

9.96%

Change vs last qtr

−250.0K (−21.1%)

Held since

2024

Orbimed Advisors LLC

13D · 8.8%

844.8K

% of company

9.02%

Change vs last qtr

−183.2K (−17.8%)

Held since

≤2021

28 more super investors behind a free account

See every manager holding ADICET Bio, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ACET on Form N-PORT; together they hold 7.5% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$2.08M	240.9K	2.57%	0.00%	June 30, 2026
FB Franklin Biotechnology Discovery Fund Franklin Strategic Series	$2.05M	225.2K	2.41%	0.18%	July 31, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$2.08M

% of company

2.57%

% of the fund

0.00%

As of

June 30, 2026

Franklin Biotechnology Discovery Fund

Franklin Strategic Series

Position value

$2.05M

% of company

2.41%

% of the fund

0.18%

As of

July 31, 2026

15 more funds behind a free account

See every fund holding ADICET Bio, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
OC Orbimed Capital GP V LLC 5%+ holder 13D · 5.9%	564.1K	6.03%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company6.030% Disclosed stake13D · 5.9% View the 13D/G filing →
OC Orbimed Capital GP Vi LLC 5%+ holder 13D · 2.9%	280.6K	3.00%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company3.000% Disclosed stake13D · 2.9% View the 13D/G filing →

Orbimed Capital GP V LLC

5%+ holder13D · 5.9%

564.1K

% of company

6.03%

Change vs last qtr

—

Held since

—

Orbimed Capital GP Vi LLC

5%+ holder13D · 2.9%

280.6K

% of company

3.00%

Change vs last qtr

—

Held since

—

9 more holders behind a free account

See every insider and 5%+ holder of ADICET Bio, Inc..

Comments